Oct 10 Bavarian Nordic A/S
* Announces initiation of Phase 2 combination trial of PROSTVAC and Ipilimumab in patients with localized prostate cancer
* Primary endpoint of study is to evaluate CD3+ T cell immune responses and secondary measures include immunologic infiltration, circulating effector T cells and regulatory T cells Source text for Eikon: Further company coverage: (Gdynia Newsroom)
Aixtron, Fujian to explore what is left of deal after U.S. veto
FRANKFURT, Dec 3 German semiconductor equipment maker Aixtron will explore with its Chinese suitor what can be salvaged of the planned takeover after a U.S. presidential order ruled the deal posed a national security risk, the company said on Saturday.